These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 24453741)

  • 21. The apparently milder course of multiple sclerosis: changes in the diagnostic criteria, therapy and natural history.
    Sorensen PS; Sellebjerg F; Hartung HP; Montalban X; Comi G; Tintoré M
    Brain; 2020 Sep; 143(9):2637-2652. PubMed ID: 32710096
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Revised Recommendations of the Consortium of MS Centers Task Force for a Standardized MRI Protocol and Clinical Guidelines for the Diagnosis and Follow-Up of Multiple Sclerosis.
    Traboulsee A; Simon JH; Stone L; Fisher E; Jones DE; Malhotra A; Newsome SD; Oh J; Reich DS; Richert N; Rammohan K; Khan O; Radue EW; Ford C; Halper J; Li D
    AJNR Am J Neuroradiol; 2016 Mar; 37(3):394-401. PubMed ID: 26564433
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hypointense lesions on T1-weighted spin-echo magnetic resonance imaging: relation to clinical characteristics in subgroups of patients with multiple sclerosis.
    van Walderveen MA; Lycklama A Nijeholt GJ; Adèr HJ; Jongen PJ; Polman CH; Castelijns JA; Barkhof F
    Arch Neurol; 2001 Jan; 58(1):76-81. PubMed ID: 11176939
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Magnetic resonance active lesions as individual-level surrogate for relapses in multiple sclerosis.
    Sormani MP; Stubinski B; Cornelisse P; Rocak S; Li D; De Stefano N
    Mult Scler; 2011 May; 17(5):541-9. PubMed ID: 21148262
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of the Central Vein Sign as a Diagnostic Imaging Biomarker in Multiple Sclerosis.
    Sinnecker T; Clarke MA; Meier D; Enzinger C; Calabrese M; De Stefano N; Pitiot A; Giorgio A; Schoonheim MM; Paul F; Pawlak MA; Schmidt R; Kappos L; Montalban X; Rovira À; Evangelou N; Wuerfel J;
    JAMA Neurol; 2019 Dec; 76(12):1446-1456. PubMed ID: 31424490
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Teriflunomide for multiple sclerosis.
    He D; Zhang C; Zhao X; Zhang Y; Dai Q; Li Y; Chu L
    Cochrane Database Syst Rev; 2016 Mar; 3(3):CD009882. PubMed ID: 27003123
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Peginterferon beta-1a improves MRI measures and increases the proportion of patients with no evidence of disease activity in relapsing-remitting multiple sclerosis: 2-year results from the ADVANCE randomized controlled trial.
    Arnold DL; Calabresi PA; Kieseier BC; Liu S; You X; Fiore D; Hung S
    BMC Neurol; 2017 Feb; 17(1):29. PubMed ID: 28183276
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis.
    Elliott C; Belachew S; Wolinsky JS; Hauser SL; Kappos L; Barkhof F; Bernasconi C; Fecker J; Model F; Wei W; Arnold DL
    Brain; 2019 Sep; 142(9):2787-2799. PubMed ID: 31497864
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Standardizing Magnetic Resonance Imaging Protocols, Requisitions, and Reports in Multiple Sclerosis: An Update for Radiologist Based on 2017 Magnetic Resonance Imaging in Multiple Sclerosis and 2018 Consortium of Multiple Sclerosis Centers Consensus Guidelines.
    Arevalo O; Riascos R; Rabiei P; Kamali A; Nelson F
    J Comput Assist Tomogr; 2019; 43(1):1-12. PubMed ID: 30015803
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessing 'No Evidence of Disease Activity' Status in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Fingolimod in Routine Clinical Practice: A Retrospective Analysis of the Multiple Sclerosis Clinical and Magnetic Resonance Imaging Outcomes in the USA (MS-MRIUS) Study.
    Weinstock-Guttman B; Medin J; Khan N; Korn JR; Lathi E; Silversteen J; Calkwood J; Silva D; Zivadinov R;
    CNS Drugs; 2018 Jan; 32(1):75-84. PubMed ID: 29270772
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fingolimod for relapsing-remitting multiple sclerosis.
    La Mantia L; Tramacere I; Firwana B; Pacchetti I; Palumbo R; Filippini G
    Cochrane Database Syst Rev; 2016 Apr; 4(4):CD009371. PubMed ID: 27091121
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Axonal damage in multiple sclerosis plaques: a combined magnetic resonance imaging and 1H-magnetic resonance spectroscopy study.
    Simone IL; Tortorella C; Federico F; Liguori M; Lucivero V; Giannini P; Carrara D; Bellacosa A; Livrea P
    J Neurol Sci; 2001 Jan; 182(2):143-50. PubMed ID: 11137520
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomized trial of stress management for the prevention of new brain lesions in MS.
    Mohr DC; Lovera J; Brown T; Cohen B; Neylan T; Henry R; Siddique J; Jin L; Daikh D; Pelletier D
    Neurology; 2012 Jul; 79(5):412-9. PubMed ID: 22786596
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase II baseline versus treatment study to determine the efficacy of raltegravir (Isentress) in preventing progression of relapsing remitting multiple sclerosis as determined by gadolinium-enhanced MRI: The INSPIRE study.
    Gold J; Marta M; Meier UC; Christensen T; Miller D; Altmann D; Holden D; Bianchi L; Adiutori R; MacManus D; Yousry T; Schmierer K; Turner B; Giovannoni G
    Mult Scler Relat Disord; 2018 Aug; 24():123-128. PubMed ID: 29990894
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New OFSEP recommendations for MRI assessment of multiple sclerosis patients: Special consideration for gadolinium deposition and frequent acquisitions.
    Brisset JC; Kremer S; Hannoun S; Bonneville F; Durand-Dubief F; Tourdias T; Barillot C; Guttmann C; Vukusic S; Dousset V; Cotton F;
    J Neuroradiol; 2020 Jun; 47(4):250-258. PubMed ID: 32014494
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relapsing-remitting multiple sclerosis: sequential enhanced MR imaging vs clinical findings in determining disease activity.
    Barkhof F; Scheltens P; Frequin ST; Nauta JJ; Tas MW; Valk J; Hommes OR
    AJR Am J Roentgenol; 1992 Nov; 159(5):1041-7. PubMed ID: 1414773
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions.
    Elliott C; Wolinsky JS; Hauser SL; Kappos L; Barkhof F; Bernasconi C; Wei W; Belachew S; Arnold DL
    Mult Scler; 2019 Dec; 25(14):1915-1925. PubMed ID: 30566027
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Daclizumab high-yield process reduced the evolution of new gadolinium-enhancing lesions to T1 black holes in patients with relapsing-remitting multiple sclerosis.
    Radue EW; Sprenger T; Vollmer T; Giovannoni G; Gold R; Havrdova E; Selmaj K; Stefoski D; You X; Elkins J
    Eur J Neurol; 2016 Feb; 23(2):412-5. PubMed ID: 26806217
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Natural history of multiple sclerosis: a unifying concept.
    Confavreux C; Vukusic S
    Brain; 2006 Mar; 129(Pt 3):606-16. PubMed ID: 16415308
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.